REFERENCES
- Aricha, R., Feferman, T., Fuchs, S., Souroujon, M.C. (2008). Ex vivo generated regulatory T cells modulate experimental autoimmune myasthenia gravis. J Immunol 180: 2132–2139.
- Aruna, B.V., Sela, M., Mozes, E. (2006). Down-regulation of T cell responses to AChR and reversal of EAMG manifestations in mice by a dual altered peptide ligand via induction of CD4+ CD25+ regulatory cells. J Neuroimmunol 177: 63–75.
- Gold, R., Schneider-Gold, C. (2008). Current and future standards in treatment of myasthenia gravis. Neurotherapeutics 5(4): 535–541.
- Graus, Y., Meng, F., Vincent, A., van Breda Vriesman, P., de Baets, M. (1995). Sequence analysis of anti-AChR antibodies in experimental autoimmune myasthenia gravis. J Immunol 154: 6382–6396.
- Guo, C.Y., Li, Z.Y., Xu, M.Q., Yuan, J.M. (2005). Preparation of an immunoadsorbent coupled with a recombinant antigen to remove anti-acetylcholine receptor antibodies in abnormal serum. J Immunol Methods 303: 142–147.
- Lefvert, A.K., Cuenoud, S., Fulpius, B.W. (1981). Binding properties and subclass distribution of anti-acetylcholine receptor antibodies in myasthenia gravis. J Neuroimmunol 1: 125–135.
- Meriggioli, M.N., Sheng, J.R., Li, L., Prabhakar, B.S. (2008). Strategies for treating autoimmunity: novel insights from experimental myasthenia gravis. Ann N Y Acad Sci 1132: 276–282.
- Psaridi-Linardaki, L., Trakas, N., Mamalaki, A., Tzartos, S.J. (2005). Specific immunoadsorption of the autoantibodies from myasthenic patients using the extracellular domain of the human muscle acetylcholine receptor α-subunit. Development of an antigen-specific therapeutic strategy. J Neuroimmunol 159: 183–191.
- Schneidewind-Muller, J.M., Winkler, R.E., Tiess, M., Muller, W., Ramlow, W. (2002). Changes in lymphocytic cluster distribution during extracorporeal immunoadsorption. Artif Organs 26(2): 140–144.
- Splendiani, G., Cipriani, S., Passalacqua, S., Stur, A., Costanzi, S., Fulignati, P., Staffolani, E., Casciani, C.U. (2003). Plasmaperfusion on tryptophan columns can improve the clinical outcome of patients affected with myasthenia gravis. Artif Cells Blood Substit Immobil Biotechnol 31(1): 69–79.
- Stieglbauer, K., Topakian, R., Schaffer, V., Aichner, F.T. (2009). Rituximab for myasthenia gravis: Three case reports and review of the literature. J Neurol Sci Epub ahead of print.
- Sundberg, L., Porath, J. (1974). Preparation of adsorbent for biospecific affinity chromatography. J Chromatology 90: 87–92.
- Takamori, M., Ide, Y. (1996). Specific removal of anti-acetylcholine receptor antibodies in patients with myasthenia gravis. Transfus Sci 17: 445–453.
- Takamori, M., Maruta, T. (2001). Immunoadsorption in myasthenia gravis based on specific ligands mimicking the immunogenic sites of the acetylcholine receptor. Ther Apher 5(5): 340–350.
- Tzartos, S.J., Kokla, A., Walgrave, S., Conti-Tronconi, B.M. (1998). Localization of the main immunogenic region of the human muscle acetylcholine receptor to residues 67–76 of the α-subunit. Proc Natl Acad Sci USA 85: 2899–2903.
- Vincent, A., Palace, J., Hilton-Jones, D. (2001). Myasthenia gravis. Lancet 357: 2122–2128.
- Yang, L., Cheng, Y., Yan, W.R., Yu, Y.T. (2004). Extracorporeal whole blood immunoadsorption of autoimmune myasthenia gravis by cellulose tryptophan adsorbent. Artif Cells Blood Substit Immobil Biotechnol 32(4): 519–528.
- Zisimopoulou, P., Lagoumintzis, G., Poulas, K., Tzartos, S.J. (2008). Antigen-specific apheresis of human anti-acetylcholine receptor autoantibodies from myasthenia gravis patients’ sera using Escherichia coli-expressed receptor domains. J Neuroimmunol 200: 133–141.